Transcriptional profiling of Vibrio cholerae O1 following exposure to human anti- lipopolysaccharide monoclonal antibodies.
Agglutination
Animals
Antibodies, Bacterial
/ administration & dosage
Antibodies, Monoclonal
/ immunology
Bacterial Outer Membrane Proteins
/ immunology
Bacterial Proteins
/ immunology
Cholera
/ immunology
Cholera Toxin
/ immunology
Disease Models, Animal
Gene Deletion
Gene Expression Profiling
Gene Expression Regulation, Bacterial
Genes, Bacterial
Host-Pathogen Interactions
Humans
Immunoglobulin G
/ immunology
Lipid A
/ immunology
Lipopolysaccharides
/ immunology
Mice
Mice, Inbred BALB C
Rabbits
Transcription Factors
/ immunology
Transcriptome
Vibrio cholerae O1
/ genetics
Virulence
antibody
cholera
enteric
immunity
mucosal
transcription
vaccine
Journal
Pathogens and disease
ISSN: 2049-632X
Titre abrégé: Pathog Dis
Pays: United States
ID NLM: 101595366
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
19
03
2020
accepted:
22
06
2020
pubmed:
27
6
2020
medline:
15
5
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
Following an episode of cholera, a rapidly dehydrating, watery diarrhea caused by the Gram-negative bacterium, Vibrio cholerae O1, humans mount a robust anti-lipopolysaccharide (LPS) antibody response that is associated with immunity to subsequent re-infection. In neonatal mouse and rabbit models of cholera, passively administered anti-LPS polyclonal and monoclonal (MAb) antibodies reduce V. cholerae colonization of the intestinal epithelia by inhibiting bacterial motility and promoting vibrio agglutination. Here we demonstrate that human anti-LPS IgG MAbs also arrest V. cholerae motility and induce bacterial paralysis. A subset of those MAbs also triggered V. cholerae to secrete an extracellular matrix (ECM). To identify changes in gene expression that accompany antibody exposure and that may account for motility arrest and ECM production, we subjected V. cholerae O1 El Tor to RNA-seq analysis after treatment with ZAC-3 IgG, a high affinity MAb directed against the core/lipid A region of LPS. We identified > 160 genes whose expression was altered following ZAC-3 IgG treatment, although canonical outer membrane stress regulons were not among them. ompS (VCA1028), a porin associated with virulence and indirectly regulated by ToxT, and norR (VCA0182), a σ54-dependent transcription factor involved in late stages of infection, were two upregulated genes worth noting.
Identifiants
pubmed: 32589220
pii: 5863188
doi: 10.1093/femspd/ftaa029
pmc: PMC7371154
pii:
doi:
Substances chimiques
Antibodies, Bacterial
0
Antibodies, Monoclonal
0
Bacterial Outer Membrane Proteins
0
Bacterial Proteins
0
Immunoglobulin G
0
Lipid A
0
Lipopolysaccharides
0
Transcription Factors
0
Cholera Toxin
9012-63-9
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R21 AI109275
Pays : United States
Informations de copyright
© FEMS 2020.
Références
Vaccine. 2016 Nov 21;34(48):5833-5836
pubmed: 27773473
FEMS Microbiol Lett. 2004 Oct 1;239(1):1-8
pubmed: 15451094
Cell Host Microbe. 2007 Oct 11;2(4):264-77
pubmed: 18005744
Infect Immun. 2018 Jun 21;86(7):
pubmed: 29712730
J Biol Chem. 2007 Apr 27;282(17):12860-70
pubmed: 17307739
Mol Microbiol. 2018 Feb;107(3):330-343
pubmed: 29152799
Microbiol Immunol. 1986;30(11):1075-83
pubmed: 3543624
PLoS One. 2010 Sep 30;5(9):
pubmed: 20927349
Infect Immun. 2004 Oct;72(10):6050-60
pubmed: 15385509
Trends Genet. 2000 Sep;16(9):404-9
pubmed: 10973069
J Infect Dis. 1982 Apr;145(4):465-73
pubmed: 7069227
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):730-4
pubmed: 9435261
BMC Bioinformatics. 2017 Nov 29;18(1):529
pubmed: 29187165
Infect Immun. 2010 Oct;78(10):4402-20
pubmed: 20679439
J Bacteriol. 2014 Feb;196(3):660-71
pubmed: 24272778
J Bacteriol. 2015 Jan;197(2):262-76
pubmed: 25368298
Clin Vaccine Immunol. 2016 May 06;23(5):427-435
pubmed: 27009211
Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5403-7
pubmed: 2052618
J Bacteriol. 2009 Sep;191(17):5398-408
pubmed: 19542276
Microb Pathog. 1987 Aug;3(2):143-7
pubmed: 2849017
J Bacteriol. 2010 Feb;192(4):955-63
pubmed: 20023022
J Bacteriol. 2011 Feb;193(4):842-53
pubmed: 21131484
Microbiology (Reading). 2005 Jul;151(Pt 7):2373-2383
pubmed: 16000727
Infect Immun. 2016 Apr 22;84(5):1478-1490
pubmed: 26930702
Trends Microbiol. 2000 Apr;8(4):189-91
pubmed: 10754579
Carbohydr Res. 1982 Mar 1;100:341-9
pubmed: 7083255
PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0007803
pubmed: 32203503
Infect Immun. 2016 Dec 29;85(1):
pubmed: 27795359
J Bacteriol. 2013 Apr;195(8):1800-8
pubmed: 23417487
mBio. 2019 Apr 23;10(2):
pubmed: 31015332
Mucosal Immunol. 2015 Jan;8(1):176-85
pubmed: 24962092
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Nature. 2002 Jun 6;417(6889):642-5
pubmed: 12050664
Genome Biol. 2015 Jan 13;16:1
pubmed: 25583448
PLoS One. 2019 Mar 7;14(3):e0213507
pubmed: 30845262
mBio. 2012 Apr 17;3(2):e00013-12
pubmed: 22511349
Infect Immun. 1994 Nov;62(11):4781-8
pubmed: 7927755
Mol Microbiol. 1994 Sep;13(6):1013-20
pubmed: 7854116
PLoS Genet. 2014 Oct 02;10(10):e1004649
pubmed: 25275371
Infect Immun. 2015 Apr;83(4):1674-83
pubmed: 25667263
Lancet. 2017 Sep 23;390(10101):1539-1549
pubmed: 28302312
Biochim Biophys Acta. 2003 Oct 15;1639(2):65-79
pubmed: 14559113
J Bacteriol. 2009 Nov;191(22):7027-38
pubmed: 19767434
Infect Immun. 1991 Dec;59(12):4310-7
pubmed: 1937792
Mol Microbiol. 2001 Mar;39(6):1595-609
pubmed: 11260476
J Bacteriol. 2008 Jul;190(13):4677-86
pubmed: 18469102
Lancet. 2012 Jun 30;379(9835):2466-2476
pubmed: 22748592
J Bacteriol. 1988 Jun;170(6):2575-83
pubmed: 2836362
J Bacteriol. 2011 Oct;193(19):5260-70
pubmed: 21804008
Nucleic Acids Res. 2013 Aug;41(14):e140
pubmed: 23716638
EMBO J. 2019 Aug 15;38(16):e101650
pubmed: 31313835
Sci Rep. 2016 Feb 19;6:20871
pubmed: 26892868
Nature. 2000 Aug 3;406(6795):477-83
pubmed: 10952301
Front Microbiol. 2020 Apr 29;11:739
pubmed: 32425907
Infect Immun. 1993 Dec;61(12):5279-85
pubmed: 8225601
Microb Pathog. 1988 Sep;5(3):169-75
pubmed: 3216777
PLoS One. 2018 Jan 2;13(1):e0190026
pubmed: 29293563
mSphere. 2019 Nov 27;4(6):
pubmed: 31776240
Infect Immun. 2009 Mar;77(3):1103-11
pubmed: 19103776
J Immunol Methods. 2015 Jul;422:111-7
pubmed: 25865265
Mol Microbiol. 2000 Feb;35(4):743-55
pubmed: 10692152
mBio. 2016 Dec 20;7(6):
pubmed: 27999163
Mol Microbiol. 1998 Jan;27(2):381-90
pubmed: 9484893
Cell. 2012 Apr 13;149(2):358-70
pubmed: 22500802
Clin Vaccine Immunol. 2012 Nov;19(11):1712-21
pubmed: 22993410
Clin Vaccine Immunol. 2014 May;21(5):777-82
pubmed: 24574537